Double-blind confirmatory study of AD-5423 (blonanserin) in patients with schizophrenia [Phase 3 study]
Latest Information Update: 16 Jun 2016
Price :
$35 *
At a glance
- Drugs Blonanserin (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 16 Jun 2016 New trial record